Osteocalcin

There are 384 papers on osteocalcin in aging research: 95 trials and 91 observational studies in people, 133 in animals, 15 in cells, 48 reviews. The newest story, Nov 12, 2026: “Natural compound curbs bone breakdown by lab-grown cells”.

Biomarker

384 papers study it191 more mention it124 findings

MeSH

22 new papers in 30 daysSee all 575 papers on osteocalcin

At a glance

Human observational studies associate osteocalcin with bone mineral density, frailty in women, and osteosarcopenia. Human exercise trials often report increases, while hormone treatment trials report increases or decreases depending on the treatment. An association with vascular dementia does not survive correction for multiple testing; an alpha-ketoglutarate trial in postmenopausal women with osteopenia shows no clear effect on osteocalcin.

124 findings in 103 papers from 1988 to 2026, 8 of them since April 2026

“positive association of OC (r = 0.32, p = 0.022) with BMD at the lumbar spine were identified after resveratrol”
Resveratrol-Induced Suppression of C-type Natriuretic Peptide Associates With Increased Vertebral Bone Density in Postmenopausal WomenJBMR plus2023doi:10.1002/jbm4.10732
  • Human trial95
  • Humans91
  • Animals133
  • Cells15

Interventions

52

Resistance training

upin humans2downin rats1

3 studies
  1. Resistance training increases osteocalcin in humans (physically active) (p = 0.015).

    “Significant Exercise × Time interactions were shown for osteocalcin (p = 0.015), OPG (p = 0.021), and sclerostin (p = 0.002), with higher concentrations 24 h after resistance exercise than following endurance exercise.”

    Human trialphysically activeserum24 h post-exercisefemalesn = 13

    Resistance and interval running exercise exert differential short-term post-exercise bone metabolic marker responses in postmenopausal

    Bone

  2. Resistance training increases osteocalcin in humans (postmenopausal) (SMD 0.65, 95% CI 0.10 to 1.20).

    “resistance exercise(SMD = 0.65, 95% CI: 0.10 to 1.20, P = 0.02)significantly increased OC levels.”

    Reviewpostmenopausalfemales

    Effects of exercise on bone metabolism in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials

    Frontiers in endocrinology

  3. Resistance training decreases osteocalcin in aging ovariectomized rats.

    “there was also a significant decrease in plasma levels of OCN (p=0.001 and 0.002) and OPG (p=0.003 and 0.014), compared with animals in the NT-Veh group.”

    Animalsin aging ovariectomized rats120 daysfemales

    The effects of strength training and raloxifene on bone health in aging ovariectomized rats

    Bone

More on Resistance training

Growth hormone

upin humans3

3 studies
  1. Growth hormone increases osteocalcin in humans (osteoporosis).

    “The bone formation markers, osteocalcin (OC) and bone alkaline phosphatase, remained high during GH treatment”

    Human trialosteoporosisrecombinant human48 weeksfemalesn = 8

    Effect of recombinant human growth hormone in elderly osteoporotic women

    Clinical endocrinology

  2. Growth hormone increases osteocalcin in humans (growth hormone deficiency) (19.4 +/- 1.7 to 34.4 +/- 4.7 micrograms/L; p < 0.004).

    “Mean serum osteocalcin concentration rose from 19.4 +/- 1.7 to 34.4 +/- 4.7 micrograms/L (p < 0.004)”

    Human trialgrowth hormone deficiencyhuman, recombinantserumInitial dose 0.125 IU/kg b.w./week; individually adjusted12 monthsmalesn = 18

    The effect of growth hormone replacement therapy on markers of bone formation and bone mineral density in elderly men

    Polskie Archiwum Medycyny Wewnetrznej

  3. Growth hormone increases osteocalcin in humans (postmenopausal osteopenia).

    “women in the GH groups showed a sustained rise in circulating osteocalcin over the entire 2-yr protocol.”

    Human trialpostmenopausal osteopeniarecombinant human20 micrograms/kg.day2 yearsfemales

    Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women

    The Journal of clinical endocrinology and metabolism

More on Growth hormone

Nordic walking

downin humans1upin humans1

2 studies
  1. Nordic walking decreases osteocalcin in humans (undercarboxylated (Glu-OC) and carboxylated (Gla-OC) forms).

    “NW caused a decrement in both forms of osteocalcin: undercarboxylated (Glu-OC) and carboxylated-type (Gla-OC).”

    Human trialundercarboxylated (Glu-OC) and carboxylated (Gla-OC) forms

    Nordic Walking Rather Than High Intensity Interval Training Reduced Myostatin Concentration More Effectively in Elderly Subjects and the Range of This Drop Was Modified by Metabolites of Vitamin D

    Nutrients

  2. Nordic walking increases osteocalcin in humans (time × group interaction versus control group) (NW 38.9 to 41.6; CON 37.1 to 37.2; effect size 0.13).

    “osteocalcin (NW: 38.9 ± 26.04 to 41.6 ± 25.09; CON: 37.1 ± 33.2 to 37.2 ± 32.29; p = 0.03; = 0.13)”

    Human trialtime × group interaction versus control groupthree times a week, at 70% of the individual maximum ability12 weeksfemalesn = 36

    Iron Status in Elderly Women Impacts Myostatin, Adiponectin and Osteocalcin Levels Induced by Nordic Walking Training

    Nutrients

More on Nordic walking

Resveratrol

no changein humans1upin rats1

2 studies
  1. Resveratrol showed no clear effect on osteocalcin in humans (no significant reduction).

    “Pooling six RCTs (eight treatment arms with 264 subjects) together identified no significant reduction of serum Ca, osteocalcin, C-terminal telopeptide of type I collagen, and procollagen I N-terminal propeptide values”

    Reviewn = 264

    Effects of resveratrol supplementation on bone biomarkers: a systematic review and meta-analysis

    Annals of the New York Academy of Sciences

  2. Resveratrol increases osteocalcin in ovariectomized rats, partially reversing OVX-induced decrease.

    “Relative levels of OCN and Runx2, ALP activity and calcification ability decreased in OVX group relative to sham group, which were partially reversed by RES treatment.”

    Animalsin ovariectomized rats, partially reversing OVX-induced decrease

    Resveratrol alleviates osteoporosis through improving the osteogenic differentiation of bone marrow mesenchymal stem cells

    European review for medical and pharmacological sciences

More on Resveratrol

Dehydroepiandrosterone

upin humans1downin humans1

2 studies
  1. Dehydroepiandrosterone increases osteocalcin in humans (steroid-induced osteoporosis in glucocorticoid-treated patients).

    “A significant elevation of serum IGF-1 and osteocalcin concentrations was found as early as after six weeks of DHEA treatment.”

    Human trialsteroid-induced osteoporosis in glucocorticoid-treated patientsmicronizedserum25-50 mg dailyas early as after six weeksfemalesn = 19

    Effect of DHEA supplementation on serum IGF-1, osteocalcin, and bone mineral density in postmenopausal, glucocorticoid-treated women

    Advances in medical sciences

  2. Dehydroepiandrosterone decreases osteocalcin in humans (hypoadrenalism).

    “In basal conditions, mean serum osteocalcin (OC) was normal and significantly decreased after DHEA treatment.”

    Human trialhypoadrenalismserum50 mg/day4 monthsn = 20

    Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism

    Journal of endocrinological investigation

More on Dehydroepiandrosterone

Cholecalciferol

no changein humans1downin humans1

2 studies
  1. Cholecalciferol showed no clear effect on osteocalcin in humans.

    “cholecalciferol supplementation alone throughout winter did not affect bone turnover markers in apparently healthy young and elderly adults, even when stratified by VDR genotype.”

    Human trialthroughout winter

    Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults

    The Journal of nutrition

  2. Cholecalciferol decreases osteocalcin in humans (Nursing home residents only).

    “serum osteocalcin significantly decreased in the nursing home residents only.”

    Human trialNursing home residents onlyserum400 or 800 IU/day1 yearn = 72

    The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects

    The Journal of clinical endocrinology and metabolism

More on Cholecalciferol

Magnesium

upin humans1upin rats1

2 studies
  1. Magnesium increases osteocalcin in humans (postmenopausal osteoporotic women) (p < 0.001).

    “Serum osteocalcin levels were significantly increased (p < 0.001)”

    Human trialpostmenopausal osteoporotic womenmagnesium citrate1,830 mg/day30 daysfemalesn = 10

    Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women

    Biological trace element research

  2. Magnesium increases osteocalcin in rats (ovariectomized rats).

    “Serum osteocalcin (a bone formation marker) in the OVX rats fed the 0.15% Mg diet was significantly higher than in the OVX rats fed 0.05% Mg.”

    Animalsovariectomized ratsdiet0.15% Mg diet versus 0.05% Mg diet42 days

    Dietary magnesium supplementation affects bone metabolism and dynamic strength of bone in ovariectomized rats

    The Journal of nutrition

More on Magnesium

Somatropin

upin humans2+88%

2 studies
  1. Somatropin increases osteocalcin in humans (osteoporotic) (88%).

    “Mean levels of the bone formation markers S-osteocalcin and S-procollagen type I propeptide increased maximally by 88 and 36% respectively after 9-12 months”

    Human trialosteoporotic9-12 monthsfemales

    Growth hormone treatment of osteoporotic postmenopausal women - a one-year placebo-controlled study

    European journal of endocrinology

  2. Somatropin increases osteocalcin in humans (10.3 +/- .86 vs. 8.0 +/- 0.5 micrograms/L; P less than 0.05).

    “A rise in serum osteocalcin (10.3 +/- .86 vs. 8.0 +/- 0.5 micrograms/L; P less than 0.05) was accompanied by increased urinary excretion of hydroxyproline”

    Human trial7 daysn = 16

    Effects of short term administration of recombinant human growth hormone to elderly people

    The Journal of clinical endocrinology and metabolism

More on Somatropin

Limosilactobacillus reuteri

no changein humans1

1 study
  1. Limosilactobacillus reuteri showed no clear effect on osteocalcin in humans (prednisolone treatment) (14.2 (95% CI −7.8 to 36.3, p =.21)).

    “After 7 d of treatment with prednisolone, the adjusted mean difference between L. reuteri treatment and placebo in percentage change of bone status indices was 14.2 (95% CI −7.8 to 36.3, p =.21) for osteocalcin”

    Human trialprednisolone treatment30 d (27 d minimum)n = 50

    Prevention of glucocorticoid-induced impairment of bone metabolism-a randomized, placebo-controlled, single centre proof-of-concept clinical trial

    JBMR plus

  2. Limosilactobacillus reuteri showed no clear effect on osteocalcin in healthy young adults receiving oral prednisolone (14.2 (95% CI -7.8 to 36.3), p = .21).

    “or in osteocalcin levels (14.2 [-7.8-36.3], p = .21)”

    Human trialin healthy young adults receiving oral prednisolone1 × 1010 CFU/d2 wkn = 46

    Prevention of glucocorticoid-induced impairment of bone metabolism-a randomized, placebo-controlled, single centre proof-of-concept clinical trial

    JBMR plus

More on Limosilactobacillus reuteri

Walking

upin humans1

1 study
  1. Walking increases osteocalcin in humans (8.51 ± 2.28 ng/mL to 9.39 ± 2.97 ng/mL).

    “When comparing the findings after the intervention to those before the intervention, significant increases were observed in the serum concentration of OC (8.51 ± 2.28 ng/mL to 9.39 ± 2.97 ng/mL, p < 0.1) and the serum concentration ICTP (4.45 ± 2.58 ng/mL to 5.31 ± 2.92 ng/mL, p < 0.1).”

    Human trialserum8-week

    Evaluating Biomarkers of Bone Health After an 8-Week Walking Program in Non-Ambulatory Stroke Survivors: A Pilot Study

    Journal of clinical medicine

  2. Walking increases osteocalcin in humans (8.51 ± 2.28 ng/mL to 9.39 ± 2.97 ng/mL (p < 0.10)).

    “The serum concentration of OC significantly increased from 8.51 ± 2.28 ng/mL to 9.39 ± 2.97 ng/mL (p < 0.10).”

    Human trial8 weeksn = 9

    Evaluating Biomarkers of Bone Health After an 8-Week Walking Program in Non-Ambulatory Stroke Survivors: A Pilot Study

    Journal of clinical medicine

More on Walking

Osteo-f

upin humans1upin mice1

1 study
  1. Osteo-f increases osteocalcin in humans (postmenopausal women; compared with placebo).

    “resulted in significant improvements in the Z-score and serum osteocalcin levels of postmenopausal women compared to the placebo”

    Human trialpostmenopausal women; compared with placeboherbal formulaserum253 mg24 weeksfemales

    An Integrative Study on the Inhibition of Bone Loss via Osteo-F Based on Network Pharmacology, Experimental Verification, and Clinical Trials in Postmenopausal Women

    Cells

  2. Osteo-f increases osteocalcin in mice (osteoporotic mice).

    “After the administration of Osteo-F to osteoporotic mice, the femoral BMD and osteocalcin in the serum and bone tissues were significantly improved.”

    Animalsosteoporotic miceherbal formulaserum and bone tissue

    An Integrative Study on the Inhibition of Bone Loss via Osteo-F Based on Network Pharmacology, Experimental Verification, and Clinical Trials in Postmenopausal Women

    Cells

More on Osteo-f

Equol + resveratrol

upin humans1

1 study
  1. Equol + resveratrol improves osteocalcin in humans.

    “Likewise, a significant change in the concentrations of OC and BAP compared to both the baseline and placebo (p ≤ 0.0001 for all, C,D) was observed after 12 months.”

    Human trial12 monthsn = 60

    Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial

    International journal of molecular sciences

  2. Equol + resveratrol improves osteocalcin in humans (p < 0.0001).

    “DPD, osteocalcin, and BAP significantly improved in the active group (p < 0.0001 for all) compared to the placebo group.”

    Human trial12 monthsfemalesn = 60

    Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial

    International journal of molecular sciences

More on Equol + resveratrol

Interval running

downin humans1

1 study
  1. Interval running decreases osteocalcin in humans (Endurance-trained versus resistance-trained females).

    “with lower 24 h concentrations in the endurance- than resistance-trained group”

    Human trialEndurance-trained versus resistance-trained femalesblood24 hfemales

    Bone biomarker concentrations at baseline and 24 h after resistance and interval running exercise in eumenorrheic females and oral contraceptive users

    Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme

More on Interval running

Ospemifene

downin humans1

1 study
  1. Ospemifene decreases osteocalcin in humans (vulvovaginal atrophy) (OC: -2.8).

    “OSPG demonstrated significant reductions in bone alkaline phosphatase (BAP: -2.5) and osteocalcin (OC: -2.8), biomarkers of bone formation.”

    Human trialvulvovaginal atrophybone60 mg/day24 monthsfemalesn = 72

    Long-term Effects of Ospemifene on densitometric and bone metabolism biomarkers in Postmenopausal Women reporting Vulvar and Vaginal Atrophy (VVA)

    Research SquarePreprint

More on Ospemifene

Combined aerobic and weight-bearing exercise

upin humans1

1 study
  1. Combined aerobic and weight-bearing exercise increases osteocalcin in humans (+29.4%, p < 0.01).

    “higher osteocalcin (+29.4%)”

    Human trial12 weeksfemalesn = 86

    Epigenetic and hormonal effects of supervised combined aerobic and weight-bearing on bone health in postmenopausal women

    Experimental gerontology

More on Combined aerobic and weight-bearing exercise

All 52

Effects

4

Dementia prediction C index

upin humans1

1 study
  1. Osteocalcin is linked with higher dementia prediction C index in humans (Adding osteocalcin to the prediction model; fivefold cross-validation) (C index from 0.84628 to 0.84642; ΔC = 0.00014).

    “Adding OCN changed the mean fivefold cross-validated C index from 0.84628 to 0.84642 (ΔC = 0.00014).”

    HumansAdding osteocalcin to the prediction model; fivefold cross-validation

    Circulating osteocalcin and incident dementia in the UK Biobank: a prospective cohort and exploratory multi-omics analysis

    Frontiers in aging neuroscience

Telomere length

no changein silico1

1 study
  1. Osteocalcin showed no clear effect on telomere length in silico.

    “reverse Mendelian randomization analysis did not indicate a significant impact of OC, MMP-3, and MMP-12 on telomere length”

    In silico

    Causal Association of Telomere Length and Loss of Bone: a Directional Mendelian Randomization Study of Multi-Outcomes

    Applied biochemistry and biotechnology

More on Telomere length

Handgrip strength

downin humans1OR 3.89

1 study
  1. Osteocalcin is linked with worse handgrip strength in humans (diabetes) (OR: 3.89, 95% CI: 1.66-9.10).

    “Multivariate logistic regression showed that a higher serum osteocalcin level was associated with worse handgrip strength (OR: 3.89, 95% CI: 1.66-9.10)”

    Humansdiabetesn = 237

    Sex Differences and Positive Dose-Response Relationships between Serum Osteocalcin Levels and Low Muscle Strength

    Gerontology

Oral dysfunction

no changein humans1

1 study
  1. Osteocalcin was not clearly linked with oral dysfunction in humans.

    “No significant association was found between the OC level and oral dysfunction.”

    Humansn = 139

    Association between Bone-Related Physiological Substances and Oral Function in Community-Dwelling Older People

    International journal of environmental research and public health

Upstream

1

Ketosis suppression

upin humans1

1 study
  1. ketosis suppression increases osteocalcin in humans (33.84 ng/mL (± 13.66) to 55.31 ng/mL (± 29.71, P2)).

    “tOCN significantly increased after P1 from 33.84 ng/mL (± 13.66) to 55.31 ng/mL (± 29.71, P2, p = 0.0138; ), and then significantly decreased following the removal of SuK (P3) to 34.02 ng/mL (± 12.05, p = 0.0253) compared to P2, returning to similar baseline P1 values.”

    Human trialthree 21-day phasesfemalesn = 10

    Ketosis Suppression and Ageing (KetoSAge) Part 2: The Effect of Suppressing Ketosis on Biomarkers Associated with Ageing, HOMA-IR, Leptin, Osteocalcin, and GLP-1, in Healthy Females

    Biomedicines

Associations

45

Bone mineral density

upin humans2downin humans1OR 1.738

3 studies
  1. Osteocalcin is associated with bone mineral density in humans (postmenopausal).

    “BMD was associated with CTX, OC, and TRAP.”

    Humanspostmenopausalbonefemalesn = 400

    Contribution of bone turnover markers (BTMs) and vitamin D to bone health in Iranian elderly women

    Journal of diabetes and metabolic disorders

  2. Osteocalcin is associated with bone mineral density in elderly patients with T2DM (p < 0.05).

    “BMD, SMI, handgrip strength and calf circumference decreased with the increasing osteocalcin concentrations (p < 0.05).”

    Humansin elderly patients with T2DMn = 224

    Serum Osteocalcin as a Risk Factor for osteosarcopenia in elderly patients with T2DM

    Research SquarePreprint

  3. Osteocalcin is associated with bone mineral density in humans (OR 1.738, 95% CI 1.136-2.660).

    “serum osteocalcin remained independently related with lower BMD (odds ratio [OR] 1.738, 95% confidence interval [CI] 1.136-2.660, p = 0.011).”

    Humansmales

    Bone status in men with heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure

    European journal of heart failure

More on Bone mineral density

Osteosarcopenia

upin humans2OR 10.84

2 studies
  1. Osteosarcopenia is associated with osteocalcin in osteosarcopenia group in elderly patients with T2DM.

    “The results showed the levels of OC, β-CTX, and PINP increased in the osteosarcopenia group.”

    Humansin osteosarcopenia group in elderly patients with T2DMn = 224

    Serum Osteocalcin as a Risk Factor for osteosarcopenia in elderly patients with T2DM

    Research SquarePreprint

  2. Osteocalcin is linked with a higher risk of osteosarcopenia in elderly patients with T2DM (OR = 10.84, 95% CI (1.24-95.00)).

    “A higher serum osteocalcin level was associated with higher risk of OS (OR = 10.84, 95% CI (1.24-95.00)) in the logistic regression model.”

    Humansin elderly patients with T2DMn = 224

    Serum Osteocalcin as a Risk Factor for osteosarcopenia in elderly patients with T2DM

    Research SquarePreprint

  3. Osteocalcin is linked with a higher risk of osteosarcopenia in humans (adjusted model).

    “In the multivariable logistic regression model, OC and CTX were associated with increased likelihood of osteosarcopenia [adjusted OR= 1.023(1.002-1.045 for OC, 4.363(1.389-15.474 for CTX)].”

    Humansadjusted model

    Association between biomarkers of bone health and osteosarcopenia among Iranian older people: The Bushehr Elderly Health (BEH) program

    BMC geriatrics

More on Osteosarcopenia

Type 2 diabetes

downin humans1downin reviews1

2 studies
  1. Type 2 diabetes is associated with osteocalcin in men with T2D (Δ-6.36 μg/L, 95% CI -9.15 to -3.57).

    “osteocalcin (men: Δ-6.36 μg/L, 95%CI -9.15 to -3.57, p < 0.001”

    Humansin men with T2Dmales

    Profiling bone status indices reveals evidence of a low-turnover bone phenotype in type 2 diabetes: findings from the DiaFALL cohort

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

  2. Type 2 diabetes is associated with osteocalcin in patients with T2DM and/or CVD.

    “Patients with type 2 diabetes mellitus (T2DM) and/or cardiovascular disease (CVD), conditions of hyperinsulinaemia, have lower levels of osteocalcin”

    Reviewin patients with T2DM and/or CVD

    Rethinking Fragility Fractures in Type 2 Diabetes: The Link between Hyperinsulinaemia and Osteofragilitas

    Biomedicines

More on Type 2 diabetes

Bone mineral density

upin humans1downin humans1

2 studies
  1. Osteocalcin is associated with bone mineral density in humans.

    “The data showed that BMD status and vitamin D levels correlated positively with serum levels of osteocalcin and total calcium and negatively with BMI and s-BAP, as shown in Table.”

    Human trial16 weeksfemalesn = 120

    Concurrent effects of high-intensity interval training and vitamin D supplementation on bone metabolism among women diagnosed with osteoporosis: a randomized controlled trial

    BMC musculoskeletal disorders

  2. Osteocalcin is associated with bone mineral density in humans (very elderly Chinese men).

    “The three turnover markers were moderately correlated to each other (P < 0.001), and all negatively associated with the bone mineral density of three sites (P < 0.05).”

    Humansvery elderly Chinese menmalesn = 1,316

    Reference intervals of β-C-terminal telopeptide of type I collagen, procollagen type I N-terminal propeptide and osteocalcin for very elderly Chinese men

    Geriatrics & gerontology international

Osteoporosis

upin humans1mixedin humans1

2 studies
  1. Osteocalcin is associated with osteoporosis in patients with T2DM.

    “multivariate logistic regression analysis revealed that age, osteocalcin, and uric acid were independent influencing factors for OP.”

    Humansin patients with T2DM

    The correlation between TyG-BMI and the risk of osteoporosis in middle-aged and elderly patients with type 2 diabetes mellitus

    Frontiers in nutrition

  2. Osteocalcin predicts osteoporosis in humans (Shanghai Chinese postmenopausal women) (AUC 0.746).

    “the best predictors for postmenopausal osteoporosis in Shanghai Chinese postmenopausal women were osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP)”

    HumansShanghai Chinese postmenopausal womenfemalesn = 331

    Association of Serum Periostin Level with Classical Bone Turnover Markers and Bone Mineral Density in Shanghai Chinese Postmenopausal Women with Osteoporosis

    International journal of general medicine

More on Osteoporosis

25-hydroxyvitamin D

downin humans1mixedin humans1

2 studies
  1. 25-hydroxyvitamin D is associated with osteocalcin in humans (change in osteocalcin modeled with change in insulin) (model R2 = 25.6%).

    “The change in OC was explained by changes in serum 25OHD and insulin (model R(2) = 25.6%).”

    Human trialchange in osteocalcin modeled with change in insulin6 weeksfemales

    Vitamin D supplementation during short-term caloric restriction in healthy overweight/obese older women: Effect on glycemic indices and serum osteocalcin levels

    Molecular and cellular endocrinology

  2. 25-hydroxyvitamin D is associated with osteocalcin in humans (adjusted for covariates) (β = −0.395, p = 0.001).

    “a significant negative association was observed between 25-OHD concentration and the BTMs; osteocalcin (β = −0.395; p = 0.001)”

    Humansadjusted for covariatesserumn = 69

    Vitamin D and Bone Health of Older Adults within Care Homes: An Observational Study

    Nutrients

More on 25-hydroxyvitamin D

Oral contraceptives

downin humans1

1 study
  1. Oral contraceptives are associated with osteocalcin in humans (Endurance-trained oral contraceptive users; active pill versus withdrawal phase).

    “lower concentrations in endurance-trained OC users during APP versus WP.”

    Human trialEndurance-trained oral contraceptive users; active pill versus withdrawal phasebloodfemales

    Bone biomarker concentrations at baseline and 24 h after resistance and interval running exercise in eumenorrheic females and oral contraceptive users

    Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme

More on Oral contraceptives

Primary osteoporosis

upin humans1

1 study
  1. Osteocalcin is associated with primary osteoporosis in humans (Community-dwelling middle-aged and older women).

    “elevated OST and PINP levels and imbalanced constitutions such as qi deficiency/yang deficiency/yin deficiency/damp-heat/blood stasis/qi stagnation indicated higher risk.”

    HumansCommunity-dwelling middle-aged and older womenfemalesn = 1,186

    Risk factors for osteoporosis and development of a risk prediction model in community-dwelling middle-aged and older women

    Chinese Journal of Gerontology

More on Primary osteoporosis

Bone resorption markers

upin humans1

1 study
  1. Osteocalcin is associated with bone resorption markers in humans.

    “OC showed positive association with bone resorption markers, also when the model was run separately for sex and age groups.”

    Humans

    Exploring the Interrelationship Among Bone Status Indices: A Structural Equation Modeling Approach Reveals the Role of Osteocalcin as a Marker of Overall Bone Turnover

    Diagnostics (Basel, Switzerland)

More on Bone resorption markers

Vascular dementia

upin humans1HR 1.159

1 study
  1. Osteocalcin is associated with vascular dementia in humans (HR 1.159; 95% CI, 1.010–1.328; nominal p = 0.035; adjusted p = 0.105).

    “The vascular dementia estimate was nominally positive (HR 1.159; 95% CI, 1.010–1.328; p = 0.035), but did not survive Holm correction”

    HumansNominal association did not survive Holm correction and weakened after excluding baseline stroke

    Circulating osteocalcin and incident dementia in the UK Biobank: a prospective cohort and exploratory multi-omics analysis

    Frontiers in aging neuroscience

More on Vascular dementia

Lumbar spine bone mineral density

upin humans1

1 study
  1. Osteocalcin is associated with lumbar spine bone mineral density in humans after resveratrol (r = 0.32).

    “Along with the significant inverse association of NTproCNP with BMD, there was a significant positive association of OC (r = 0.32, p = 0.022) with BMD in the lumbar spine.”

    Human trialafter resveratrol24‐month

    Resveratrol-Induced Suppression of C-type Natriuretic Peptide Associates With Increased Vertebral Bone Density in Postmenopausal Women

    JBMR plus

Lumbar spine bone mineral density

upin humans1

1 study
  1. Osteocalcin is associated with lumbar spine bone mineral density in humans After resveratrol in postmenopausal women with mild osteopenia (r = 0.32).

    “positive association of OC (r = 0.32, p = 0.022) with BMD at the lumbar spine were identified after resveratrol”

    Human trialAfter resveratrol in postmenopausal women with mild osteopenialumbar spinefemales

    Resveratrol-Induced Suppression of C-type Natriuretic Peptide Associates With Increased Vertebral Bone Density in Postmenopausal Women

    JBMR plus

More on Lumbar spine bone mineral density

Cholecalciferol

mixedin humans1

1 study
  1. Cholecalciferol is associated with osteocalcin in humans (interaction with weight loss (caloric restriction)).

    “There was an interaction between vitamin D intake and weight on serum OC, insulin, glucose and markers of insulin sensitivity (p < 0.05).”

    Human trialinteraction with weight loss (caloric restriction)2500 IU/d6 weeksfemales

    Vitamin D supplementation during short-term caloric restriction in healthy overweight/obese older women: Effect on glycemic indices and serum osteocalcin levels

    Molecular and cellular endocrinology

More on Cholecalciferol

All 45

Funding

4 grants since 2016

National Institute of Arthritis and Musculoskeletal and Skin Diseases$1.2MGouvernement du Canada | Canadian Institutes of Health ResearchCA$1.1M

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 9Jan 2026: 17Feb 2026: 18Mar 2026: 17Apr 2026: 9May 2026: 11Jun 2026: 13Jul 2026: 5Aug 2026: 3Sep 2026: 11Oct 2026: 15Nov 2026: 11139 papers in 12 months
Phytomedicine

Natural compound curbs bone breakdown by lab-grown cells

Lab experiments found that carabrone reduced bone-resorbing activity while having limited effects on measured cell signals involved in coordinating bone formation.Lab experiments found that carabrone reduced bone-resorbing activity while having limited effects on measured cell signals involved in coordinating bone formation.

Animal cell studyBones and joints
Cell Death Discovery

Loss of a regulatory protein worsened bone loss in mice

Experiments found that mice lacking SIRT5, a protein that modifies other proteins, had poorer bone formation and more severe bone loss than normal mice.Experiments found that mice lacking SIRT5, a protein that modifies other proteins, had poorer bone formation and more severe bone loss than normal mice.

Mouse studyBones and joints

See all 575 papers on osteocalcin